Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Successful re-introduction of recombinant human erythropoietin following antibody induced pure red cell aplasia.

× No keyword cloud information.

5 in total

1. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project.

Authors: Charles L Bennett; Denis Cournoyer; Kenneth R Carson; Jerome Rossert; Stefano Luminari; Andrew M Evens; Francesco Locatelli; Steven M Belknap; June M McKoy; E Alison Lyons; Benjamin Kim; Rishi Sharma; Stacey Costello; Edwin B Toffelmire; George A Wells; Hans A Messner; Paul R Yarnold; Steven M Trifilio; Dennis W Raisch; Timothy M Kuzel; Allen Nissenson; Lay-Cheng Lim; Martin S Tallman; Nicole Casadevall
Journal: Blood Date: 2005-08-11 Impact factor: 22.113

2. Improvement in erythropoieis-stimulating agent-induced pure red-cell aplasia by introduction of darbepoetin-α when the anti-erythropoietin antibody titer declines spontaneously.

Authors: Hajeong Lee; Jaeseok Yang; Hyosang Kim; Ju Won Kwon; Kook-Hwan Oh; Kwon Wook Joo; Yon Su Kim; Curie Ahn; Jin Suk Han; Suhnggwon Kim
Journal: J Korean Med Sci Date: 2010-10-26 Impact factor: 2.153

Successful re-introduction of recombinant human erythropoietin following antibody induced pure red cell aplasia.

1. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project.

2. Improvement in erythropoieis-stimulating agent-induced pure red-cell aplasia by introduction of darbepoetin-α when the anti-erythropoietin antibody titer declines spontaneously.

3. Anti-erythropoietin antibodies followed by endogenous erythropoietin production in a dialysis patient.

4. Pure red cell aplasia due to antibody against erythropoietin in hemodialysis patients.

5. Drug-induced hematologic syndromes.